Analysts See $-0.53 EPS for Omeros Corporation (OMER)

April 22, 2018 - By Dolores Ford

Omeros Corporation (NASDAQ:OMER) LogoInvestors sentiment decreased to 1.3 in 2017 Q4. Its down 1.56, from 2.86 in 2017Q3. It dived, as 14 investors sold Omeros Corporation shares while 29 reduced holdings. 31 funds opened positions while 25 raised stakes. 21.94 million shares or 0.43% less from 22.04 million shares in 2017Q3 were reported.
Mutual Of America Mngmt Limited Liability Co holds 0.03% or 109,137 shares in its portfolio. Malaga Cove Capital Limited Co accumulated 0.14% or 12,477 shares. United Cap Financial Advisers Ltd reported 101,672 shares. Stoneridge Inv Prns Ltd Liability Corp has invested 0.07% in Omeros Corporation (NASDAQ:OMER). State Street Corp has 0% invested in Omeros Corporation (NASDAQ:OMER). Pnc Fincl Grp has invested 0% in Omeros Corporation (NASDAQ:OMER). Citigroup Inc reported 23,417 shares or 0% of all its holdings. Jane Street Ltd Liability Co has 0% invested in Omeros Corporation (NASDAQ:OMER) for 25,042 shares. Northern Tru Corporation holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 600,392 shares. Northwestern Mutual Wealth Mngmt Co invested in 0% or 63 shares. Stifel Fincl holds 0.02% or 342,192 shares. Raymond James And stated it has 36,840 shares or 0% of all its holdings. Trexquant Invest Lp holds 0.02% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 11,421 shares. Royal Financial Bank Of Canada holds 0% or 1,200 shares in its portfolio. California State Teachers Retirement Sys reported 71,709 shares.

Since January 3, 2018, it had 0 buys, and 2 sales for $1.36 million activity. Kelbon Marcia S. also sold $1.34 million worth of Omeros Corporation (NASDAQ:OMER) shares.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.53 EPS on May, 9.They anticipate $0.29 EPS change or 120.83 % from last quarter’s $-0.24 EPS. After having $-0.25 EPS previously, Omeros Corporation’s analysts see 112.00 % EPS growth. The stock decreased 6.03% or $0.9 during the last trading session, reaching $14.03. About 871,625 shares traded. Omeros Corporation (NASDAQ:OMER) has declined 3.39% since April 22, 2017 and is downtrending. It has underperformed by 14.94% the S&P500.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 6 analysts covering Omeros (NASDAQ:OMER), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Omeros had 15 analyst reports since November 2, 2017 according to SRatingsIntel. The rating was maintained by Wedbush with “Buy” on Tuesday, November 28. H.C. Wainwright maintained it with “Buy” rating and $30.0 target in Thursday, December 14 report. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Friday, March 23 with “Buy” rating. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Monday, March 5 with “Buy” rating. WBB Securities maintained the stock with “Buy” rating in Monday, March 26 report. As per Wednesday, November 29, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, January 23 by H.C. Wainwright. The firm earned “Hold” rating on Friday, March 2 by Needham. The company was maintained on Thursday, April 19 by H.C. Wainwright. The company was downgraded on Friday, March 23 by Wedbush.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $677.45 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: